**Section 1.** Patients could continue on a non-biologic disease-modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, sulfasalazine or hydroxychloroquine) and systemic retinoids if the medication had been used for ≥12 weeks with a stable dose for ≥4 weeks prior to randomisation. Previous exposure to tumour necrosis factor inhibitor (TNFi) agents was permitted, provided that therapy was discontinued ≥8 weeks (≥4 weeks for etanercept) prior to randomisation. Use of non-steroidal anti-inflammatory drugs (NSAIDs), oral corticosteroids (≤10 mg/day prednisone or equivalent) and low-potency topical corticosteroids (applied only to sensitive areas other than the evaluated target lesion) were allowed if stable for ≥14 days prior to randomisation. Doses of non-biologic DMARDs, systemic retinoids and NSAIDs were required to remain stable for the duration of the double-blind period, except if dose reduction was necessary for intolerance. Dose changes for non-biologic DMARDs and systemic retinoids during the open-label period had to follow protocol-specified guidelines. The following were permitted during the open-label phase only: topical vitamin D analogues, topical retinoids, shampoo containing corticosteroids, topical tar and salicylic acid (except on the scalp), medium to high potency corticosteroids (potency ≥ triamcinolone 0.1%) and phototherapy.